Literature DB >> 8169113

A Ki-1-positive cell line expressing Epstein-Barr virus antigens, established from a child with Ki-1-positive lymphoma.

M Shimakage1, T Dezawa, S Tamura, T Tabata, N Aoyagi, M Koike, H Inoue, M Yutsudo, A Hakura, N Ikegami.   

Abstract

We report here the establishment of a CD30 (Ki-1) antigen-positive cell line 'Ki-JK' from a child with anaplastic large cell lymphoma. We characterized this cell line and show that: (i) Ki-JK cells do not grow in soft agar but infrequently produce a tumor or suppressed growth when injected into nude mice; (ii) Ki-JK cells expressed Epstein-Barr virus (EBV) antigens, EBV-associated nuclear antigen-2 and latent membrane protein; (iii) Ki-JK cells are labelled by in situ hybridization using an RNA probe derived from the BamHI W fragment of EBV, and (iv) polymerase chain reaction demonstrates the presence of an EBV BamHI W sequence in DNA of lymphoma and Ki-JK cells. These results suggest an etiological role for EBV in the development of some cases of Ki-1-positive lymphomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8169113     DOI: 10.1159/000150340

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  6 in total

1.  Macrophage involvement in Epstein-Barr virus-related tumors.

Authors:  Misuzu Shimakage; Haruhiko Sakamoto
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

2.  Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation.

Authors:  Irina Bonzheim; Martin Irmler; Margit Klier-Richter; Julia Steinhilber; Nataša Anastasov; Sabine Schäfer; Patrick Adam; Johannes Beckers; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

3.  Next-generation sequencing identifies deregulation of microRNAs involved in both innate and adaptive immune response in ALK+ ALCL.

Authors:  Julia Steinhilber; Michael Bonin; Michael Walter; Falko Fend; Irina Bonzheim; Leticia Quintanilla-Martinez
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

4.  Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.

Authors:  Yuki Uchihara; Fumihito Ueda; Kenji Tago; Yosuke Nakazawa; Tomoyuki Ohe; Tadahiko Mashino; Shigenobu Yokota; Tadashi Kasahara; Hiroomi Tamura; Megumi Funakoshi-Tago
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

5.  Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

Authors:  Samuel Y Ng; Noriaki Yoshida; Amanda L Christie; Mahmoud Ghandi; Neekesh V Dharia; Joshua Dempster; Mark Murakami; Kay Shigemori; Sara N Morrow; Alexandria Van Scoyk; Nicolas A Cordero; Kristen E Stevenson; Maneka Puligandla; Brian Haas; Christopher Lo; Robin Meyers; Galen Gao; Andrew Cherniack; Abner Louissaint; Valentina Nardi; Aaron R Thorner; Henry Long; Xintao Qiu; Elizabeth A Morgan; David M Dorfman; Danilo Fiore; Julie Jang; Alan L Epstein; Ahmet Dogan; Yanming Zhang; Steven M Horwitz; Eric D Jacobsen; Solimar Santiago; Jian-Guo Ren; Vincent Guerlavais; D Allen Annis; Manuel Aivado; Mansoor N Saleh; Amitkumar Mehta; Aviad Tsherniak; David Root; Francisca Vazquez; William C Hahn; Giorgio Inghirami; Jon C Aster; David M Weinstock; Raphael Koch
Journal:  Nat Commun       Date:  2018-05-22       Impact factor: 14.919

6.  EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.

Authors:  Yuki Uchihara; Kenji Tago; Hiroomi Tamura; Megumi Funakoshi-Tago
Journal:  Mol Oncol       Date:  2020-11-19       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.